These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 33095871)

  • 1. Association of ABO blood group with bleeding severity in patients with bleeding of unknown cause.
    Mehic D; Hofer S; Jungbauer C; Kaider A; Haslacher H; Eigenbauer E; Rejtő J; Schwartz D; Jilma B; Ay C; Pabinger I; Gebhart J
    Blood Adv; 2020 Oct; 4(20):5157-5164. PubMed ID: 33095871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of ABO Blood Group on Thromboembolic and Bleeding Complications in Patients with Left Ventricular Assist Devices.
    Tscharre M; Wittmann F; Kitzmantl D; Schlöglhofer T; Cichra P; Lee S; Eichelberger B; Wadowski PP; Laufer G; Wiedemann D; Panzer S; Zimpfer D; Gremmel T
    Thromb Haemost; 2023 Mar; 123(3):336-346. PubMed ID: 36402132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determinants of bleeding phenotype in adult patients with moderate or severe von Willebrand disease.
    de Wee EM; Sanders YV; Mauser-Bunschoten EP; van der Bom JG; Degenaar-Dujardin ME; Eikenboom J; de Goede-Bolder A; Laros-van Gorkom BA; Meijer K; Hamulyák K; Nijziel MR; Fijnvandraat K; Leebeek FW;
    Thromb Haemost; 2012 Oct; 108(4):683-92. PubMed ID: 22918553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombin-generating potential, plasma clot formation, and clot lysis are impaired in patients with bleeding of unknown cause.
    Hofer S; Ay C; Rejtö J; Wolberg AS; Haslacher H; Koder S; Pabinger I; Gebhart J
    J Thromb Haemost; 2019 Sep; 17(9):1478-1488. PubMed ID: 31177606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reassessment of ABO blood group, sex, and age on laboratory parameters used to diagnose von Willebrand disorder: potential influence on the diagnosis vs the potential association with risk of thrombosis.
    Favaloro EJ; Soltani S; McDonald J; Grezchnik E; Easton L; Favaloro JW
    Am J Clin Pathol; 2005 Dec; 124(6):910-7. PubMed ID: 16416741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between ABO blood groups and von Willebrand factor, ADAMTS13 and factor VIII in patients undergoing hemodialysis.
    Rios DR; Fernandes AP; Figueiredo RC; Guimarães DA; Ferreira CN; Simões E Silva AC; Carvalho MG; Gomes KB; Dusse LM
    J Thromb Thrombolysis; 2012 May; 33(4):416-21. PubMed ID: 22466813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relationship between ABO histo-blood group, factor VIII and von Willebrand factor.
    O'Donnell J; Laffan MA
    Transfus Med; 2001 Aug; 11(4):343-51. PubMed ID: 11532189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of ABO(H) and I blood group system development with von Willebrand factor and Factor VIII plasma levels in children and adolescents.
    Klarmann D; Eggert C; Geisen C; Becker S; Seifried E; Klingebiel T; Kreuz W
    Transfusion; 2010 Jul; 50(7):1571-80. PubMed ID: 20210927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The ABO blood group genotype and factor VIII levels as independent risk factors for venous thromboembolism.
    Tirado I; Mateo J; Soria JM; Oliver A; Martínez-Sánchez E; Vallvé C; Borrell M; Urrutia T; Fontcuberta J
    Thromb Haemost; 2005 Mar; 93(3):468-74. PubMed ID: 15735796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Models for prediction of factor VIII half-life in severe haemophiliacs: distinct approaches for blood group O and non-O patients.
    Fischer K; Pendu R; van Schooten CJ; van Dijk K; Denis CV; van den Berg HM; Lenting PJ
    PLoS One; 2009 Aug; 4(8):e6745. PubMed ID: 19707594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High proportion of patients with bleeding of unknown cause in persons with a mild-to-moderate bleeding tendency: Results from the Vienna Bleeding Biobank (VIBB).
    Gebhart J; Hofer S; Panzer S; Quehenberger P; Sunder-Plassmann R; Hoermann G; Eigenbauer E; Haslacher H; Kepa S; Kyrle PA; Eichinger S; Knöbl P; Eischer L; Mannhalter C; Ay C; Pabinger I
    Haemophilia; 2018 May; 24(3):405-413. PubMed ID: 29388750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P).
    Michiels JJ; Berneman ZN; van der Planken M; Schroyens W; Budde U; van Vliet HH
    Blood Coagul Fibrinolysis; 2004 Jun; 15(4):323-30. PubMed ID: 15166918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of fibrinolysis on bleeding phenotype in moderate and severe von Willebrand disease.
    De Wee EM; Klaij K; Eikenboom HC; Van Der Bom JG; Fijnvandraat K; Laros-Van Gorkom BA; Mauser-Bunschoten EP; Meijer K; Goverde G; Van Der Linden PW; Rijken DC; Leebeek FW;
    Haemophilia; 2012 May; 18(3):444-51. PubMed ID: 21910790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of von Willebrand disease.
    Rodeghiero F; Castaman G
    Semin Hematol; 2005 Jan; 42(1):29-35. PubMed ID: 15662613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of ABO blood group on von Willebrand factor tests in healthy Saudi blood donors.
    Alharbi A; Hassan SB; Al-Momen AK; Al-Saleh K; Nasr R; Kohgear H; Owaidah T
    Blood Coagul Fibrinolysis; 2018 Mar; 29(2):211-215. PubMed ID: 29369083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baseline factor VIII plasma levels and age at first bleeding in patients with severe forms of von Willebrand disease.
    Siboni SM; Biguzzi E; Caiani V; Mistretta C; Bucciarelli P; Peyvandi F
    Haemophilia; 2016 Jul; 22(4):564-9. PubMed ID: 26843468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. von Willebrand factor and factor VIII levels after desmopressin are associated with bleeding phenotype in type 1 VWD.
    Atiq F; Schütte LM; Looijen AEM; Boender J; Cnossen MH; Eikenboom J; de Maat MPM; Kruip MJHA; Leebeek FWG
    Blood Adv; 2019 Dec; 3(24):4147-4154. PubMed ID: 31834934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BLOOD TYPE O IS A RISK FACTOR FOR HYPERFIBRINOLYSIS AND MASSIVE TRANSFUSION AFTER SEVERE INJURY.
    DeBot M; Eitel AP; Moore EE; Sauaia A; Lutz P; Schaid TR; Hadley JB; Kissau DJ; Cohen MJ; Kelher MR; Silliman CC
    Shock; 2022 Dec; 58(6):492-497. PubMed ID: 36548640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distribution of von Willebrand factor levels in young women with and without bleeding symptoms: influence of ABO blood group and promoter haplotypes.
    Lethagen S; Hillarp A; Ekholm C; Mattson E; Halldén C; Friberg B
    Thromb Haemost; 2008 Jun; 99(6):1013-8. PubMed ID: 18521502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.